min xu

Prof. Dr. min xu

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2023 in Molecules
Verified
Journal Article
Open access
PDF file
XSXiaojuan Sun
Xiaojuan Sun
HDHongbo Deng
Hongbo Deng
TSTengyun Shu
Tengyun Shu
MXmin xu
min xu
LSLi-Hua Su
Li-Hua Su
HLHaizhou Li
Haizhou Li
Panax notoginseng (Burk.) F. H. is a genuine medicinal material in Yunnan Province. As accessories, P. notoginseng leaves mainly contain protopanaxadiol saponins. The preliminary findings have indicated that P. notoginseng leaves contribute to its significant pharmacological effects and have been administrated to tranquilize and treat cancer and nerve injury. Saponins from P. notoginseng leaves were isolated and purified by different chromatographic methods, and the structures of 1–22 were elucidated mainly through comprehensive analyses of spectroscopic data. Moreover, the SH-SY5Y cells protection bioactivities of all isolated compounds were tested by establishing L-glutamate models for nerve cell injury. As a result, twenty-two saponins, including eight dammarane saponins, namely notoginsenosides SL1-SL8 (1–8), were identified as new compounds, together with fourteen known compounds, namely notoginsenoside NL-A3 (9), ginsenoside Rc (10), gypenoside IX (11), gypenoside XVII (12), notoginsenoside Fc (13), quinquenoside L3 (14), notoginsenoside NL-B1 (15), notoginsenoside NL-C2 (16), notoginsenoside NL-H2 (17), notoginsenoside NL-H1 (18), vina-ginsenoside R13 (19), ginsenoside II (20), majoroside F4 (21), and notoginsenoside LK4 (22). Among them, notoginsenoside SL1 (1), notoginsenoside SL3 (3), notoginsenoside NL-A3 (9), and ginsenoside Rc (10) showed slight protective effects against L-glutamate-induced nerve cell injury (30 µM).

28 June 2023 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
BWBaoqu Wang
Baoqu Wang
XTXiaoxue Tian
Xiaoxue Tian
XLXing-Cng Li
Xing-Cng Li
KCKui Cheng
Kui Cheng
MXmin xu
min xu

15 July 2022 in Protein & Cell
Verified
Journal Article
Open access
PDF file
DZDaming Zuo
Daming Zuo
YCYu Chen
Yu Chen
JCJian-Piao Cai
Jian-Piao Cai
HYHao-Yang Yuan
Hao-Yang Yuan
JWJun-Qi Wu
Jun-Qi Wu
MXmin xu
min xu
The twenty-first century has already recorded more than ten major epidemics or pandemics of viral disease, including the devastating COVID-19. Novel effective antivirals with broad-spectrum coverage are urgently needed. Herein, we reported a novel broad-spectrum antiviral compound PAC5. Oral administration of PAC5 eliminated HBV cccDNA and reduced the large antigen load in distinct mouse models of HBV infection. Strikingly, oral administration of PAC5 in a hamster model of SARS-CoV-2 omicron (BA.1) infection significantly decreases viral loads and attenuates lung inflammation. Mechanistically, PAC5 binds to a pocket near Asp49 in the RNA recognition motif of hnRNPA2B1. PAC5-bound hnRNPA2B1 is extensively activated and translocated to the cytoplasm where it initiates the TBK1-IRF3 pathway, leading to the production of type I IFNs with antiviral activity. Our results indicate that PAC5 is a novel small-molecule agonist of hnRNPA2B1, which may have a role in dealing with emerging infectious diseases now and in the future.

20 March 2024 in Journal of Hazardous Materials
Verified
Journal Article
Closed access
BWBaoqu Wang
Baoqu Wang
YKYating Kong
Yating Kong
XTXiaoxue Tian
Xiaoxue Tian
MXmin xu
min xu

2 December 2021 in Chemistry & Biodiversity
Verified
Journal Article
Closed access
PDF file
SCShu‐Xia Chen
Shu‐Xia Chen
JXJia‐Yao Xiang
Jia‐Yao Xiang
JHJia‐Xin Han
Jia‐Xin Han
YFYang‐ Feng
Yang‐ Feng
HLHai‐Zhou Li
Hai‐Zhou Li
MXmin xu
min xu

1 September 2019 in Fitoterapia
Verified
Journal Article
Closed access
CGChen Gu
Chen Gu
AYAi-Ping Yin
Ai-Ping Yin
HYHao-Yang Yuan
Hao-Yang Yuan
KYKong Yang
Kong Yang
JLJia Luo
Jia Luo
MXmin xu
min xu